×
About 11,435 results

Disparities Exist in Diabetes-Related ED Visits
https://www.medscape.com/viewarticle/974720

May 27th, 2022 - Wide disparities exist in diabetes-related emergency department (ED) use between racial and ethnic groups, rural and urban patients, and Medicare and Medicaid-insured adults versus those who were privately insured between 2008 and 2017, a serial cross-sectional study indicates. All-cause ED visits increased by over 50% during the same period even though substantial health reforms were made duri...

Combined Use of Anakinra, Etanercept, and BETA-2 Score Linked With Improved Islet Cell Transplant Outcomes
https://www.medscape.com/viewarticle/974633

May 26th, 2022 - NEW YORK (Reuters Health) - In a single center's 20-year experience with pancreatic islet cell transplantation, patients with sustained graft survival were more likely to have had combination treatment with anakinra plus etanercept (one or more infusions) and a BETA-2 score of 15 or higher - reflecting insulin independence - within one year, researchers say. "Our findings with anakinra plus eta...

Glucocorticoid Abnormalities Boost Infections
https://www.medscape.com/viewarticle/974650

May 26th, 2022 - Researchers published the study covered in this summary on medRxiv.org as a preprint that has not yet been peer reviewed. Key Takeaways The newly derived Infections in Patients With Endocrinopathies (ICARO) questionnaire is a patient self-report tool that showed promise in clinical testing as a simple and cost-effective way to identify patients at increased risk for infections and evaluate the ...

Why Is Long-Term Weight Loss So Difficult? It's Biology, Not Willpower!
https://www.medscape.com/viewarticle/974209

May 25th, 2022 - It's an all-too-common story. A patient loses weight after changing his or her diet and physical activity. Donna Ryan Comprehensive lifestyle intervention (behavior changes around diet and physical activity) is foundational to weight loss efforts, including perhaps the addition of drugs, devices, or surgery. These interventions have been shown to produce weight loss associated with many health ...

Experts Endorse Plant-Based Diet for Type 2 Diabetes Remission
https://www.medscape.com/viewarticle/974591

May 25th, 2022 - Many adults can achieve remission of type 2 diabetes with a primary intervention consisting of a diet that emphasizes whole, plant-based foods, according to a new publication from the American College of Lifestyle Medicine (ACLM). The document was developed to assist clinicians treating adults with type 2 diabetes, with the goal of remission using diet as a primary intervention. A panel of 15 e...

Tirzepatide: 'Exciting' and Promising in Lowering A1c
https://www.medscape.com/viewarticle/974144

May 23rd, 2022 - This transcript has been edited for clarity. The FDA just approved tirzepatide as the first dual GIP/GLP-1 (glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1) receptor agonist on the market for treating type 2 diabetes. The indication that it currently has is reducing glucose in patients with type 2 diabetes who are not successful with diet and exercise. It doesn't yet have a...

Debate Continues on Combination Therapy for Hypothyroidism
https://www.medscape.com/viewarticle/974330

May 20th, 2022 - It's "critically important" for clinicians to recognize that not all patients with hypothyroidism are fully treated with levothyroxine (LT4) and some may need combination treatment with triiodothyronine (LT3) despite normal levels of thyroid stimulating hormone (TSH), according to thyroid expert Antonio C. Bianco, MD, PhD. Speaking to a crowded room at the recent American Association of Clinica...

Tirzepatide's Retail Price Set at About $12,666 Per Year
https://www.medscape.com/viewarticle/974390

May 20th, 2022 - Tirzepatide (Mounjaro) — the new twincretin approved by the US Food and Drug Administration (FDA) for glycemic control in patients with type 2 diabetes — was priced by Lilly, the company that will market the drug, at a list price of $974.33 for four weekly doses regardless of dose size, a cost that adds up to about $12,666 per year, according to a statement made on May 20 by a Lilly spokesperso...

Could New Therapy for Food 'Cues' Improve Weight Loss?
https://www.medscape.com/viewarticle/974246

May 19th, 2022 - An intensive 1-year behavior therapy program aimed at changing a person's response to food "cues" might help people with obesity lose a modest amount of weight, a randomized clinical trial suggests. "Patients who are food-cue sensitive often feel out of control with their eating; they cannot resist food and/or cannot stop thinking about food," said lead author Kerri N. Boutelle, PhD. "Behaviora...

Environmental Health Is Going to Get Very Personal
https://www.medscape.com/viewarticle/974010

May 19th, 2022 - Raghu G. Mirmira, MD, PhD Earth Day 2022 has come — and gone. Gone, because the day has passed, and for many, so has the message. Earth Day is a call to action not just for a day but for a lifetime. If you reflect on the awful global events that we've witnessed in recent years — cataclysmic floods, wildfires, extreme heat waves, melting of polar ice — you're probably thinking that governments n...

Pancreatic Involvement in COVID-19: What Do We Know?
https://www.medscape.com/viewarticle/974291

May 19th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. MADRID — There is increasing evidence of the impact that SARS-CoV-2 infection has on patients with diabetes. It involves the relationship between COVID-19 and new diagnoses of diabetes and blood glucose disorders, among others, in the post–COVID-19 period. These topics were addressed at the XXXI...

A1c and Blood Pressure Fluctuations Predict Fracture Risk
https://www.medscape.com/viewarticle/973814

May 18th, 2022 - Not long after my own personal 40-year parts warranty expired, I sprinted a block to retrieve my daughter from her late-afternoon activity lest I incur the wrath of the activity director. My left ankle caught the curb edge, snapping the styloid process of my left fibula along with the fourth metatarsal — unknown to me until I got home, hobbled inside, and shrieked when my daughter inadvertently...

Biotin: Good for Hair and Nails, Bad for Thyroid Lab Tests
https://www.medscape.com/viewarticle/974203

May 18th, 2022 - A sizeable proportion of people use cosmetic products containing enough biotin to interfere with several laboratory measurements, including those of thyroid function, new research finds.   The clinical takeaway, two endocrinologists told Medscape Medical News during the American Association of Clinical Endocrinology (AACE) Annual Meeting 2022, is that if an asymptomatic patient's thyroid test c...

Does COVID-19 Raise the Risk for Diabetes?
https://www.medscape.com/viewarticle/972835

May 17th, 2022 - This transcript has been edited for clarity. Does having had a COVID-19 infection increase your risk for the development of diabetes subsequently? Some data say yes and other data say no. No matter what, it's obviously important to screen people for diabetes routinely, pandemic or not. Remember, screening should start at age 35. For over a decade, we have known that SARS-type viruses bind to be...

Keeping Thyroid Hormone Treatment On Target Is Key for the Heart
https://www.medscape.com/viewarticle/974130

May 17th, 2022 - A new study highlights the importance of avoiding both exogenous hyperthyroidism and exogenous hypothyroidism to decrease cardiovascular risk and death among patients receiving thyroid hormone treatment. "Our findings suggest that clinicians should make every effort to maintain euthyroidism in patients on thyroid hormone treatment, regardless of underlying cardiovascular risk, particularly in v...

Abaloparatide Works in 'Ignored Population': Men With Osteoporosis
https://www.medscape.com/viewarticle/974036

May 16th, 2022 - The anabolic osteoporosis treatment abaloparatide (Tymlos, Radius Health) works in men as well as women, new data indicate.   Findings from the Abaloparatide for the Treatment of Men With Osteoporosis (ATOM) randomized, double-blind, placebo-controlled, phase 3 study were presented last week at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2022. Abaloparatide, a subcu...

Diabetes Doubles Risk of Death From COVID-19; East–West Divide?
https://www.medscape.com/viewarticle/973944

May 13th, 2022 - An umbrella review of meta-analyses/systematic reviews of COVID-19 outcomes in patients with and without diabetes from around the world found overall worse outcomes in patients with COVID-19 who had diabetes — with geographic differences. Diabetes has been known to be a risk factor for poorer prognosis in COVID-19, but this is the first time a study has looked at the risks while factoring in th...

First Fatty Liver Guidelines for Endocrinology, Primary Care
https://www.medscape.com/viewarticle/973928

May 13th, 2022 - New clinical practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) are the first to be targeted specifically to primary care and endocrinology clinical settings. They include 34 evidence-based clinical practice recommendations for screening, diagnosis, management, and referral, presented in a table and an algorithm flow chart as well as detailed text. ...

Low-Calorie Ketogenic Diet Improves Immune Function
https://www.medscape.com/viewarticle/973967

May 13th, 2022 - MADRID, Spain — According to the latest evidence, the ketogenic diet is emerging as an effective strategy not only to promote weight loss, but also to manage many comorbidities associated with obesity, including COVID-19. This development was revealed during the 8th International Scientific Symposium New Frontiers in Scientific Research, organized by PronoKal Group and held in Barcelona, Spain....

Tirzepatide (Mounjaro) Gets FDA Approval for Type 2 Diabetes
https://www.medscape.com/viewarticle/974013

May 13th, 2022 - The "Twincretin" era for treating patients with type 2 diabetes has begun, with the US Food and Drug Administration's (FDA's) approval of tirzepatide for this indication on May 13, making it the first approved agent that works as a dual agonist for the two principal human incretins. Tirzepatide represents "an important advance in the treatment of type 2 diabetes," said the FDA's Patrick Archdea...